Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors - a thrombin generation-guided pilot study

Haemophilia

Volumn 19, Issue 5, 2013, Pages 782-789

  Livnat, T ^a   Martinowitz, U ^a   Azar Avivi, S ^a   Zivelin, A ^a   Brutman Barazani, T ^a   Lubetsky, A ^a   Kenet, G ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Factor VIII; Haemophilia A; Immune tolerance; Inhibitors; RFVIIa; Thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ADULT; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; HEMOPHILIA A; HEMOSTASIS; HUMAN; INFANT; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

FACTOR VIII; HAEMOPHILIA A; IMMUNE TOLERANCE; INHIBITORS; RFVIIA; THROMBIN GENERATION;

ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMOSTASIS; HUMANS; INFANT; ISOANTIBODIES; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT PROTEINS; THROMBIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883052898     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12181     Document Type: Article

References (37)

1. Pipe SW, Valentino LA. Optimizing outcomes for patients with severe haemophilia A. Haemophilia 2007; 13(Suppl. 4): 1-16.
2. Hermans C, De Moerloose P, Fischer K et al.; European Haemophilia Therapy Standardisation Board. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia 2011; 17: 383-92.
3. Gouw SC, van der Bom JG, Van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
4. Astermark J. Prevention and prediction of inhibitor risk. Haemophilia 2012; 18(Suppl. 4): 38-42.
5. Haya S, Moret A, Cid AR et al. Inhibitors in haemophilia A: current management and open issues. Haemophilia 2007; 13(Suppl. 5): 52-60.
6. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
7. zAstermark J, Donfield SM, DiMichele DM, Gringeri A et al.; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
8. Kenet G, Stenmo CB, Blemings A et al. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost 2010; 103: 351-9.
9. Dargaud Y, Béguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
10. Trossaërt M, Regnault V, Sigaud M, Boisseau P, Fressinaud E, Lecompte T. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost 2008; 6: 486-93.
11. Santagostino E, Mancuso ME, Tripodi A et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8: 737-43.
12. Lossing TS, Kasper CK, Feinstein DI. Detection of factor VIII inhibitors with the partial thromboplastin time. Blood 1977; 49: 793-7.
13. Dargaud Y, Sorensen B, Shima M, Hayward C, Srivastava A, Negrier C. Global haemostasis and point of care testing. Haemophilia 2012; 18(Suppl. 4): 81-8.
14. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15: 904-10.
15. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
16. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
17. Nair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global haemostasis and their applications in bleeding disorders. Haemophilia 2010; 16(Suppl. 5): 85-92.
18. Livnat T, Martinowitz U, Zivelin A, Rima D, Kenet G. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. Thromb Haemost 2011; 105: 688-95.
19. Klintman J, Astermark J, Berntorp E. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Br J Haematol 2010; 151: 381-6.
20. Doshi BS, Gangadharan B, Doering CB, Meeks SL. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition. PLoS ONE 2012; 7: e48172.
21. Hemker HC, Giesen P, Al Dieri R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
22. Livnat T, Zivelin A, Martinowitz U, Salomon O, Seligsohn U. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost 2006; 4: 192-200.
23. Sørensen B, Dargaud Y, Kenet G et al. On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia 2012; 18: 255-62.
24. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10: 1478-85.
25. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
26. Dargaud Y, Wolberg AS, Luddington R et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res 2012; 130: 929-34.
27. Gissel M, Whelihan MF, Ferris LA, Mann KG, Rivard GE, Brummel-Ziedins KE. The influence of prophylactic factor VIII in severe haemophilia A. Haemophilia 2012; 18: 193-9.
28. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
29. Gringeri A, Fischer K, Karafoulidou A et al. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 2011; 17: 630-5.
30. Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 2008; 14: 782-6.
31. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
32. Kavakli K, Makris M, Zulfikar B et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
33. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
34. Brown SA, Barnes C, Curtin J et al. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Intern Med J 2012; 42: 1243-50.
35. Boadas A, Fernández-Palazzi F, De Bosch NB, Cedeño M, Ruiz-Sáez A. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela. Haemophilia 2011; 17: 422-7.
36. Rodriguez-Merchan EC, Jimenez-Yuste V, Gomez-Cardero P, Alvarez-Roman M, Martin-Salces M, Rodriguez de la Rua A. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience. Haemophilia 2010; 16: 84-8.
37. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.